Nintedanib Slows FVC Decline in Systemic Sclerosis-Related ILD
The tyrosine kinase inhibitor nintedanib (Ofev) appeared to slow the progression of systemic sclerosis–associated interstitial lung disease, reported the phase III SENSCIS trial.In the primary endpoint analysis, the adjusted annual rate of decrease in forced vital capacity (FVC) was 52.4 mL among patients assigned to nintedanib compared with 93.3 mL for patients on placebo (P=0.04), reported Oliver Distler, MD, of the University Hospital Zurich in Switzerland.The 41.0 mL per-year difference (95% CI 2.9-79.0) between the t
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies